Patent 8436150 was granted and assigned to Amgen on May, 2013 by the United States Patent and Trademark Office.
This invention relates to compositions and methods for treating c-Kit associated disorders such as fibrosis, and more particularly, to compositions containing humanized c-Kit antibodies.